Journal Information
Vol. 42. Issue S1.
Pages 27 (October 2020)
Share
Share
Download PDF
More article options
Vol. 42. Issue S1.
Pages 27 (October 2020)
OP 18
Open Access
Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia
Visits
1312
E. Aladag1,*, H. Goker2, H. Demiroglu2, S. Aksu2, N. Sayınalp2, I. Haznedaroglu2, O. Ozcebe2, Y. Buyukasık2
1 Hacettepe University Department Hematology, Ankara, Turkey
2 Hacettepe University Department Hematologyacettepe University Department Hematology, Ankara, Turkey
This item has received

Under a Creative Commons license
Article information
Full Text

Objective: Aplastic anemia (AA) is a life-threatening disorder of hematologic stem cell which, if untreated, may be associated with significant morbidity and mortality due to the recurrent infections or bleeding. Currently, the first treatment option is allogeneic hematopoietic stem cell transplant (allo-HSCT) for patients younger than 40 years. Bone marrow is recommended as the stem cell source due to less graft versus host disease (GVHD) risk and better outcomes than peripheral blood (PB)-derived stem cell. Recently, a few data of PB-derived allo-HSCT in AA has been published, due to its easy applicability and early engraftment advantage. The aim of this study is to share the data of AA patients who have underwent PB-derived allo-HSCT in our bone marrow transplantation center.

Methodology: Twenty-seven patients who underwent PB-derived allo-HSCT from human leukocyte antigen matched sibling donors were analyzed retrospectively.

Results: The median follow-up time of the patients was 95.2 months (range, 4.8–235 months). The 10-year survival was 89%. The median neutrophil and platelet engraftment time was 11 days (range, 9–16 days) and 13 days (range, 11–29 days, respectively. Primary platelet engraftment failure was observed in only 1 patient (3.7%). Acute and chronic GVHD observed in 2 (7.4%) and 3 (11.1%) patients, respectively. Neutropenic fever was observed in 13 (44.8%) of patients until the engraftment after allo-HSCT. One patient died due to CMV infections, two died due to septic shock secondary to fungal infection.

Conclusion: This study demonstrated that PB is the stem cell source of choice for patients with SAA.

Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools